NCT04360070 (KetCat) is a NA clinical trial of Ketamine Hydrochloride in Cardiac Arrest, Out-Of-Hospital, sponsored by Fraser Health.

Who is sponsoring NCT04360070?

NCT04360070 is sponsored by Fraser Health.

What drugs are being tested in NCT04360070?

Interventions in NCT04360070: Ketamine Hydrochloride.

What condition does NCT04360070 study?

NCT04360070 studies Cardiac Arrest, Out-Of-Hospital, Ketamine, Neurologic Manifestations.

Is NCT04360070 still recruiting?

NCT04360070 is currently status unknown. Last updated 10 January 2023.

Last reviewed 2023-01-10 · How we verify

NCT04360070: KetCat

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Application of Ketamine for Sedation in Patients With Cardiac Arrest - - KetCat (KETamine in Cardiac ArresT) Study

Status unknown NA Last updated 10 January 2023

What this trial tests

NA trial testing Ketamine Hydrochloride in Cardiac Arrest, Out-Of-Hospital in 24 participants. Status unknown.

Timeline

28 February 2022

Primary endpoint
9 December 2023

12 December 2023

Quick facts

Lead sponsor	Fraser Health
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	prevention
Enrollment	24
Start date	28 February 2022
Primary completion	9 December 2023
Estimated completion	12 December 2023
Sites	1 location across Canada

Drugs / interventions tested

Ketamine Hydrochloride — full drug profile →

Conditions studied

Cardiac Arrest, Out-Of-Hospital — all drugs for Cardiac Arrest, Out-Of-Hospital →
Ketamine — all drugs for Ketamine →
Neurologic Manifestations — all drugs for Neurologic Manifestations →

Sponsor

Fraser Health — full company profile →

Who can join

19 and older, any sex, with Cardiac Arrest, Out-Of-Hospital or Ketamine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Recent evidence suggests ketamine may attenuate harmful cellular cascades taking place after brain injury that result in permanent damage. The investigators are interested in researching the application of this in the setting of cardiac arrest. Following cardiac arrest, the brain is deprived oxygen for a period of time, leading to the imitation of these harmful cellular processes. The investigators hypothesize that patients who receive ketamine as part of their standard sedation procedures during cardiac arrest treatment have better neurological functioning compared to those who do not.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Ketamine and Esketamine in Clinical Trials: FDA-Approved and Emerging Indications, Trial Trends With Putative Mechanistic Explanations.
Vekhova KA, Namiot ED, Jonsson J, Schiöth HB. · · 2025 · cited 17× · PMID 39428602 · DOI 10.1002/cpt.3478
Ketamine Terminating Persistent Ventricular Tachycardia.
Fahhoum R, Abaid B, Ellis Z, Lynch AJ, et al · · 2024 · cited 1× · PMID 39295802 · DOI 10.1016/j.jaccas.2024.102466

Verify or expand the search:

Other trials of Ketamine Hydrochloride

Trials testing the same drug.

NCT05603104 — Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First- · Phase 3 · recruiting
NCT06090422 — Ketamine for Combined Depression and Alcohol Use Disorder · Phase 1, PHASE2 · not yet recruiting
NCT06496750 — Ketamine for Methamphetamine Use Disorder · Phase 2 · recruiting
NCT05973851 — The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Us · Phase 3 · recruiting
NCT06366334 — Study of IV Ketamine for Emergency Department Treatment of Adolescent Suicidal Ideation · NA · recruiting

Other recruiting trials for Cardiac Arrest, Out-Of-Hospital

Currently open trials in the same condition.

NCT07041086 — Prehospital ECPR in Moravia Silesia Region · recruiting
NCT07026773 — Validity of ICU Clinician's Appraisal of Proportionality in CPR · recruiting
NCT06491186 — Pulse Checks Using Femoral Artery B-Mode Ultrasound With Compressibility Assessment · recruiting
NCT05376267 — Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (P-ICECAP) · NA · recruiting
NCT05482945 — CardioPulmonary Resuscitation With Argon (CPAr) Trial · Phase 2 · recruiting

Other Fraser Health trials

Trials by the same sponsor.

NCT07437703 — Labour Pain Relief Options: Video Versus Pamphlet for Easing Fear of Birth and Improving Preparedness in Pregnant Patien · NA · not yet recruiting
NCT06856161 — A Novel Blood Test as a Biomarker in Mental Health · recruiting
NCT06867458 — Steriwave ICU Pilot Study · NA · completed
NCT05824338 — Testing the Feasibility of Using Ropivacaine in Spinal Anesthesia for Patients With Lower Back Surgery · EARLY_PHASE1 · recruiting
NCT06019078 — pEEG Monitoring Effect on Delirium, Ventilator Days, and PICS · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04360070 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fraser Health
Last refreshed: 10 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04360070.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing